Table 12.
Most successful grants in terms of their cutting-edge innovation outputs, commercialisation through patents and tangible market penetration of some of the discoveries
| Project acronym (and ID) | Diagnostic tool | Model | Total cost (million EUR) | EC contribution (million EUR) | Application | |
|---|---|---|---|---|---|---|
| AD | ADDIA (674474) | Peripheral blood diagnostic biomarker kit | h | 4.99 | 4.99 | Diagnostic tools |
| AD | VERDAD (223671) | World’s first in-vitro diagnostic (IVD) blood test for accurate AD diagnosis—PreADx | h | 3.37 | 2.36 | Diagnostic tools |
| AD | NeuroLF (229999) | Small head adjusted PET scanner development | h | 3.20 | 2.25 | Diagnostic tools |
| BC | MAMMA (628919) | Spatio-temporal modelling MRI mediated substantial improvement in diagnostic accuracy and efficiency | AI | 0.24 | 0.24 | Diagnostic tools |
| BC | MammaPrint (672570) | Evolutionary BC Diagnostic Test—(MammaPrint®), as described in WO2002/103320 | h | 4.05 | 4.05 | Diagnostic tools |
| PC | NANOZ-ONIC (682286) | Development of an innovative biosensor for the non-invasive, painless and real-time detection of volatile biomarkers in the exhaled breath of patients | A, AI | 1.92 | 1.92 | Diagnostic tools |
| BC | EPITRON (518417) | This discovery has later led to the establishment of truly innovative targeted oncology TNF drugs | a | 13.70 | 10.90 | Drug development or testing |
| BC | TRIDENT (37686) | This discovery has later led to the establishment of truly innovative targeted oncology TNF drugs | a | 2.50 | 2.07 | Drug development or testing |
| BC | MET-CANCER THERAPY (509804) | This discovery has later led to the establishment of truly innovative targeted oncology HGF Receptor tyrosine kinase (RTK) Met drugs | a | 0.22 | 0.22 | Drug development or testing |
| BC | NANOMA (224594) | Nanorobotic delivery systems to improve the administration of drugs | h, AI | 3.90 | 2.46 | Drug development or testing |
| BC | DDRESPONSE (259893) | Olaparib/Lynparza as the first PARP inhibitor approved in Europe and the US in December 2014 | a | 8.17 | 6.00 | Drug development or testing |
| BC | ONCOLYTIC-HERPES (340060) | Oncolytic herpes simplex viruses (oHSVs) targeted at cancer cells | a | 2.48 | 2.48 | Drug development or testing |
| BC | MERIT (601939) | BioNtech—The first vaccination with the highly individualized Mutanome RNAs, targeting patient-individual mutations | a | 7.79 | 5.96 | Drug development or testing |
| BC | BIOVALID (684862) | BIOVALID was boosted by the approval of palbociclib in EU in November 2016 | h | 0.68 | 0.68 | Drug development or testing |
| BC | NoCanTher (685795) | Potential treatment leap—clinical trial granted authorisation at the end of project cycle | a, h, AI | 7.11 | 7.11 | Drug development or testing |
| BC | ONCOTHERANOSTICS (795272) | Advanced Theranostic Nanomedicines related to PD-L1 checkpoint inhibitor drugs | a | 0.26 | 0.26 | Drug development or testing |
| BC | SMARTRIOX (811744) | Potentially breakthrough discovery—Targeted nanoparticles-based drug delivery system development for BC | a, h | 2.85 | 1.99 | Drug development or testing |
| PC | RV001 (879817) | Potentially breakthrough discovery—RhoVac is developing the first prophylatic vaccine against metastasis | h | 5.27 | 2.50 | Drug development or testing |
| BC | RATHER (258967) | Phase Ib/II clinical trial of a novel kinase inhibitor drug called ‘taselisib’ | h | 7.81 | 6.00 | Development of treatments or medical devices |
| BC | LIGHT2NANOGENE(624888) | Cell surgery via nanotechnology | h | 0.28 | 0.28 | Development of treatments or medical devices |
| AD | NEURAM (204053) | potentially breakthrough discovery—Commercialization opportunity mentioned | a | 4.27 | 4.27 | Development of treatments or medical devices |
| BC | INTHER (725151) | The world’s first device-based laser immunotherapy, imILTCLS | h | 2.14 | 2.14 | Development of treatments or medical devices |
| BC | BigMedilytics (780495) | Big Data sets for 11 million EU patients | AI | 16.95 | 15.00 | Development of treatments or medical devices |
| BC | B2B (801159) | Potentially breakthrough discovery | h, AI | 3.80 | 3.80 | Development of treatments or medical devices |
| BC | REGENERA (812002) | Development of polyurethanesther capable of inducing breast tissue regeneration after mastectomy | a | 2.70 | 1.89 | Development of treatments or medical devices & prevention measures |
| BC | Olfactomics Surgery (848682) | FDA breakthrough designation for the MEDICAL DEVICE was obtained | h, AI | 2.65 | 1.85 | Development of treatments or medical devices |
| BC | ENVIROGENOMARKER (S226756) | Development of Biomarkers of Environmental Pollutant Toxicity | h | 4.86 | 3.50 | Prevention measures |
| AD | CILMI (247620) | Computational Intelligence in Lifestyle Management Infrastructure | AI | 0.21 | 0.21 | Prevention measures |
| AD | VirtualBrain Cloud (826421) | Revolutionary cloud-based brain simulation platform to support personalized diagnostics and treatments in neurodegenerative diseases | AI | 15.01 | 15.01 | Development of treatments or medical devices & prevention measures |
Source: authors’ elaboration based on data processing results
Where:
a—animal model
h—human model
AI—AI/in silico/computational models